
Kiran Mazumdar-Shaw: Beer, brewing and biotech
Good Bad Billionaire
Biocon's Bold Shift: From Brewing to Biotech
This chapter explores Biocon's strategic pivot to the pharmaceutical sector, emphasizing its success in manufacturing generic medicines and producing insulin. It highlights the company's IPO triumph, the rise of its self-made billionaire leader, and the controversies faced during its ambitious journey in the global market.
00:00
Transcript
Play full episode
Remember Everything You Learn from Podcasts
Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.